This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
Genomic Biomarker Testing
PEACE-3 Trial
PROfound Trial
PSMAfore Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
PSMAddition Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
BOND-003 Cohort P
CORE-001 Study
CORE-008
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Daniel D. Joyce, MD, MS
Bladder Cancer
Non-Muscle Invasive Bladder Cancer
Ashish Kamat, MD
Muscle-Invasive Bladder Cancer
Advanced & Metastatic Bladder Cancer (mUC)
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher® Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
mCRPC with Bone Metastasis
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
Testicular, Penile & Rare GU Malignances
Testicular Cancer
Functional Urology
Functional Urology
Alan J. Wein, MD, PhD (hon.)
Urologic Catheters - CAUTI Challenges
Videos
Exclusives
Conferences
Disparities: Social Determinants of Health
Exclusive Collaborations
Health Policy in Urological Diseases
Independent Medical Education
Journal Clubs
Practice Guidelines Reviews
The Prostate Cancer Foundation
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Functional Urology
Men's Health
Pelvic Health
Actionable Clinical Data
Bladder Cancer
NMIBC with CIS: Evidence, Practice & Emerging Research
Risk-Stratified NMIBC Management
Trials in Progress
Prostate Cancer
Localized Prostate Cancer
CLARIFY
ESCAPE
FORT
NRG-GU 0101
RTIRE
High Risk BCR HSPC
ARASTEP
Oligometastatic Prostate Cancer
METANOVA
mHSPC
ARASEC
ASPIRE
MEVPRO-3
mCRPC
ECLIPSE
LEGION-100
MEVPRO-1 & 2
PROMISE
SECuRE
Bladder Cancer
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SNMMI 2026
ASCO 2026
AUA 2026
APCCC 2026
PSMA and Beyond 2026
All Conferences
View All
PCF
UroAlert - GU Oncology Daily
June 15, 2026
Videos
Peer-to-Peer Clinical Conversations
Extended Data Cut: CAN-2409 with Valacyclovir and Radiation for Localized Prostate Cancer - Mark Garzotto
M Garzotto
Mark Garzotto presents an extended data cut from the CAN-2409 trial.
View
EV-PRIME: Enfortumab Vedotin and Pembrolizumab with Radiation in Patients Declining Cystectomy - Vadim Koshkin
Vadim Koshkin
Vadim Koshkin outlines a phase 1/2 bladder-preservation trial combining enfortumab vedotin and pembrolizumab with concurrent radiation in muscle invasive bladder cancer.
View
Beyond the Abstracts
Safety of Transurethral Resection of Bladder Tumor in Octogenarians: A NSQIP Analysis - Beyond the Abstract
Optimal Treatment Duration in Metastatic Renal Cell Carcinoma Patients Responding to Immune Checkpoint Inhibitors: Should We Treat Beyond Two Years? - Beyond the Abstract
Conference Coverage
ASCO 2026: Cabozantinib + Nivolumab versus Sunitinib in Patients with Advanced RCC and Bone Metastasis: Updated Subgroup Analysis of the Phase 3 CheckMate-9ER Trial
ASCO 2026: Magnitude and Timing of Clinical Benefit Associated with Pathological Complete Response in Perioperative MIBC: A Reconstructed IPD Analysis of NIAGARA Trial
ASCO 2026: Cost-Effectiveness Analysis of First-Line Therapies for Advanced Urothelial Carcinoma from a U.S. Payer Perspective.
AUA 2026: AMPLIFY: A Phase 3 Study of 64Cu-SAR-bisPSMA Positron Emission Tomography in Participants with Biochemical Recurrence of Prostate Cancer
AUA 2026: PATAPSCO: Durvalumab in Combination with BCG for BCG-Naïve, High-Risk NMIBC: Primary Results from a US-Based, Phase IIIb, Open-Label, Single-Arm, Multicenter Study
Articles
Editor Selected Abstracts and Commentaries
Bladder Cancer
Xpert® bladder Cancer monitor urine test for non-muscle-invasive bladder cancer surveillance: a prospective clinical trial.
Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in patients with high body mass index or diabetes mellitus.
Study of Bladder Cancer Detection in Standard White Light Versus AI-Supported Endoscopy-02 (RAISE-02)-A Randomized Controlled Non-Inferiority Trial.
Penile & Urethral Cancers
Survival Outcomes of Penile Cancer Patients undergoing Primary Surgery: Experience from a Tertiary Cancer Care Centre in South India.
Renal Cancer
Early Progressive Disease During Nivolumab Plus Ipilimumab Therapy Predicts Poor Survival in Japanese Patients with Advanced Renal Cell Carcinoma: A Single-Center 12-Week Landmark Study.
Feasibility and Safety of a Ketogenic Diet During Systemic Therapy for Metastatic Renal Cell Carcinoma: Results from the Cetorein Pilot Study.
Prostate Cancer
Robust Meta-Analysis of a Clinical Cell-Cycle Risk (CCR) Score Demonstrates Broadly Applicable Metastasis and Disease-Specific Mortality Risk Stratification in Men With Localized Prostate Cancer.
PSA persistence in the PSMA PET era: reassessing a risk factor after radical prostatectomy.
Phenotyping Prostate Cancer in a National Health System Using Large Language Models.
Impact of PSMA-Based Radiopharmaceuticals on the Clinical Management of Prostate Cancer.
Biomarkers for Precision Prognosis in Prostate Cancer: Imaging, Molecular, and Integrated Approaches.
Expression of progranulin (GP88) protein appears as an independent prognostic factor for clinical progression in high-risk prostate cancer patients.
How Will PSMAddition Impact the Management of Prostate Cancer?
FDA Approves Truqap Combination for PTEN-Deficient Androgen Pathway Modulation-Naïve or -Sensitive Prostate Cancer
LuRa: Efficacy and Safety of Radium-223 Following [177Lu]Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer - Beyond the Abstract
Real-World Effectiveness and Treatment Persistence of Darolutamide, Apalutamide, and Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer: A Multicenter Study - Beyond the Abstract
Testicular Cancer
Real-World Evidence of Treatment Patterns, Time to Real-World Progression, and Overall Survival of Patients With Testicular Germ Cell Tumors Receiving Palliative Chemotherapy in the United States.
CONNECT WITH US
Questions or Comments? Email us at
editors@urotoday.com
Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523
You are receiving this email because you have chosen to receive emails from UroToday.
Add us to your address book
View this email as a web page
Forward to a colleague
Manage your subscriptions
Unsubscribe
Copyright ©2026 Digital Science Press, LLC
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free
